Comparison Chart Protagonist Therapeutics, Inc.

Stocks

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-24 EDT			5-day change	1st Jan Change
154.72 ^USD	+0.26%		-2.46%	+77.15%

08-13	Protagonist Therapeutics Insider Sold Shares Worth $14,890,799, According to a Recent SEC Filing	MT
08-11	Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says	MT

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	PROTAGONIST THERAPEUTICS, INC.	Other Biotechnology & Medical Research	+0.26%	-2.46%	+77.15%	+169.17%	+211.50%	9.99B